FindTrial
Sign In

Combination of immune checkpoint inhibitors plus chemotherapy and risk of pneumonitis: an observational, retrospective pharmacovigilance study

Combination of immune checkpoint inhibitors plus chemotherapy and risk of pneumonitis: an observational, retrospective pharmacovigilance study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200059067
Enrollment
Unknown
Registered
2022-04-23
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonitis

Interventions

None listed

Sponsors

The First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. From January 1, 2015 to September 30, 2021, patients who received PD-1/PD-L1 inhibitors for various reasons (Nivolumab, Pembrolizumab, Cemiplimab, Atezolizumab, Avelumab, Durvalumab, Ipilimumab and Tremelimumab).

Exclusion criteria

Exclusion criteria: 1. Adverse drug reactions did not include pneumonitis; 2. ICIs other than specific 8 ICIs; 3. The reported role of ICIs other than suspected and interacting; 4. Missing >50% or some essential clinical data such as drug names.

Design outcomes

Primary

MeasureTime frame
Incident pneumonitis;—

Countries

China

Contacts

Public ContactKejing Tang

The First Affiliated Hospital, Sun Yat-Sen University

tangkj@mail.sysu.edu.cn+86 13802946566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026